Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7605379rdf:typepubmed:Citationlld:pubmed
pubmed-article:7605379lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C1956346lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C0003595lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C0439793lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:7605379lifeskim:mentionsumls-concept:C1711411lld:lifeskim
pubmed-article:7605379pubmed:issue1lld:pubmed
pubmed-article:7605379pubmed:dateCreated1995-8-10lld:pubmed
pubmed-article:7605379pubmed:abstractTextIn several populations, the apolipoprotein E (apo E) allele epsilon 4 is associated with high concentration of plasma total and low density lipoprotein (LDL)-cholesterol and coronary artery disease (CAD). We determined the apo E phenotypes of 309 patients with angiographically verified CAD and 38 patients without CAD by isoelectric focusing and Western blotting. In men with CAD, the plasma total and LDL-cholesterol increased according to apo E phenotype in the following order: E3/2 < E3/3 < E4/3 < E4/4 (P = 0.03 for total cholesterol, P = 0.007 for LDL-cholesterol). In women, there was a similar trend (P = 0.22 for total cholesterol, P = 0.15 for LDL-cholesterol). The relative frequency of men with three vessel CAD increased (P = 0.43) together with LDL-cholesterol levels (P = 0.05) according to apo E phenotype E3/2, E3/3, E4/3, E4/4. Total and LDL-cholesterol levels were higher in patients with three vessel CAD than in patients with less serious types of CAD (P = 0.02 for total cholesterol, P = 0.007 for LDL-cholesterol). The relative frequency of patients with myocardial infarction increased according to apo E phenotype (P = 0.51). Both in men and women, there were no differences between apo E phenotypes in age at occurrence of the first myocardial infarction. The apo E allele frequencies of patients with CAD vs. without CAD were 2.3% vs. 1.3% for epsilon 2, 79.0% vs. 76.3% for epsilon 3 and 18.7% vs. 22.4% for epsilon 4. There were no statistically significant differences in apo E allele or phenotype frequencies between patients with CAD and without CAD or between patients with CAD and the general Finnish population. Our results support previous studies in suggesting that the apo E allele epsilon 4 is a risk factor for atherosclerosis, which affects plasma total and LDL-cholesterol. In addition, our results suggest that the apo E allele determines the severity of CAD.lld:pubmed
pubmed-article:7605379pubmed:languageenglld:pubmed
pubmed-article:7605379pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:citationSubsetIMlld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7605379pubmed:statusMEDLINElld:pubmed
pubmed-article:7605379pubmed:monthAprlld:pubmed
pubmed-article:7605379pubmed:issn0021-9150lld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:KoivulaTTlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:EhnholmCClld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:JokelaHHlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:SaleniusJ PJPlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:NikkiläMMlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:LehtinenSSlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:EbelingFFlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:LehtimäkiTTlld:pubmed
pubmed-article:7605379pubmed:authorpubmed-author:SistoTTlld:pubmed
pubmed-article:7605379pubmed:issnTypePrintlld:pubmed
pubmed-article:7605379pubmed:day7lld:pubmed
pubmed-article:7605379pubmed:volume114lld:pubmed
pubmed-article:7605379pubmed:ownerNLMlld:pubmed
pubmed-article:7605379pubmed:authorsCompleteYlld:pubmed
pubmed-article:7605379pubmed:pagination83-91lld:pubmed
pubmed-article:7605379pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:meshHeadingpubmed-meshheading:7605379-...lld:pubmed
pubmed-article:7605379pubmed:year1995lld:pubmed
pubmed-article:7605379pubmed:articleTitleApolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women.lld:pubmed
pubmed-article:7605379pubmed:affiliationDepartment of Biomedical Sciences, University of Tampere, Finland.lld:pubmed
pubmed-article:7605379pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7605379pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7605379pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7605379lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7605379lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7605379lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7605379lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7605379lld:pubmed